Form 4: Evolent Health CFO Receives Significant Equity Grant Under Incentive Plan

Evolent Health's Chief Financial Officer, John Paul Johnson, was granted 25,461 restricted stock units as part of the company's annual incentive compensation plan, vesting over three years.

Summary

• John Paul Johnson, Chief Financial Officer of Evolent Health, Inc. (EVH), acquired 25,461 shares of Class A Common Stock on July 1, 2025.
• These shares represent restricted stock units (RSUs) granted pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The granted RSUs will vest over three years: 34% on July 1, 2026, 33% on July 1, 2027, and the remaining 33% on July 1, 2028.
• This grant constitutes a portion of the annual award cycle, with the initial part of the award having been granted on March 3, 2025.
• The grant was contingent upon the approval by the company's shareholders for the issuance of additional shares under the 2015 Omnibus Incentive Compensation Plan, which occurred on June 5, 2025, at the Annual Meeting.
• Following this transaction, Mr. Johnson's beneficial ownership totals 309,245 shares, which includes previously reported restricted stock units.

Sentiment

Score: 7

Explanation: The document reports a routine, positive event for the company's executive compensation strategy, aligning management incentives with long-term performance. It's a standard insider transaction, not indicative of major positive or negative news beyond its specific scope.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's interests with long-term shareholder value through a multi-year vesting schedule.
• Shareholder approval of additional shares for the incentive plan demonstrates support for the company's executive compensation strategy and its ability to attract and retain key talent.

Future Outlook

The vesting schedule for the restricted stock units extends through July 1, 2028, indicating a long-term retention and incentive strategy for the Chief Financial Officer, aligning his future compensation with the company's performance over several years.

Industry Context

This transaction is a standard practice in the healthcare technology and services industry, where executive compensation often includes equity grants like restricted stock units to align management incentives with long-term company performance and shareholder value. Such grants are crucial for retaining key leadership in a competitive talent market.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with multi-year vesting is a common executive compensation practice across the healthcare technology sector, similar to companies like Teladoc Health (TDOC) or Veeva Systems (VEEV), which utilize equity grants to retain key talent and incentivize long-term performance.
• The grant size of 25,461 RSUs for a Chief Financial Officer is within the typical range for a company of Evolent Health's market capitalization, comparable to similar grants observed at mid-cap healthcare IT firms.
• Shareholder approval for increasing shares under incentive plans is a standard corporate governance practice, ensuring alignment between executive compensation and shareholder interests, consistent with benchmarks set by proxy advisory firms like ISS and Glass Lewis.

Corporate Governance

Related Party Transactions

• The grant of 25,461 restricted stock units to John Paul Johnson, the Chief Financial Officer, constitutes a related party transaction as part of his executive compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CFO aligns his long-term interests with shareholder value through performance-based vesting. The shareholder approval of the incentive plan indicates support for the company's compensation strategy.
• Employees: While specific to the CFO, such grants are part of a broader incentive compensation framework that can motivate other key employees by demonstrating the company's commitment to equity-based rewards.

Next Steps

• Vesting of 34% of the granted restricted stock units on July 1, 2026.
• Vesting of 33% of the granted restricted stock units on July 1, 2027.
• Vesting of 33% of the granted restricted stock units on July 1, 2028.

Key Dates

Keywords

Evolent Health, EVH, John Paul Johnson, Chief Financial Officer, CFO, Restricted Stock Units, RSU, Incentive Compensation Plan, SEC Form 4, Insider Transaction, Equity Grant, Shareholder Approval